Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P20231
UPID:
TRYB2_HUMAN
Alternative names:
Tryptase II
Alternative UPACC:
P20231; D2E6S0; D2E6S2; O95827; Q15664; Q9UQI6; Q9UQI7
Background:
Tryptase beta-2, also known as Tryptase II, is the predominant neutral protease found in mast cells, playing a crucial role in their activation-degranulation response. This enzyme is integral to the mast cells' function, which are key players in the body's immune system, particularly in allergic reactions and inflammation.
Therapeutic significance:
Understanding the role of Tryptase beta-2 could open doors to potential therapeutic strategies. Its involvement in mast cell activation suggests it could be a target for treating allergic conditions and inflammatory diseases, offering a pathway to novel treatments.